Lexaria files IND with FDA for phase 1b hypertension trial of DehydraTECH-CBD

Lexaria Bioscience Corp.

Submitted IND to FDA on Jan 29, 2024, for phase 1b trial HYPER-H23-1 in stage 1 or 2 hypertension.
Primary objective: evaluate safety and tolerability; secondary: blood pressure reduction and pharmacokinetics.
IND review takes minimum 30 days; trial start subject to FDA effectiveness and funding.
This marks formal regulatory scrutiny toward pharmaceutical commercial registration for DehydraTECH technology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.